Tongtong Huo, Wei Wu, Xiaoliang Chen, 等. Deep learning-based multimodal data fusion in bone tumor management: Advances in clinical decision support[J]. 智能肿瘤学, 2025,1(3):204-215.
Tongtong Huo, Wei Wu, Xiaoliang Chen, et al. Deep learning-based multimodal data fusion in bone tumor management: Advances in clinical decision support[J]. Intelligent Oncology, 2025, 1(3): 204-215.
Tongtong Huo, Wei Wu, Xiaoliang Chen, 等. Deep learning-based multimodal data fusion in bone tumor management: Advances in clinical decision support[J]. 智能肿瘤学, 2025,1(3):204-215.DOI: 10.1016/j.intonc.2025.06.005.
Tongtong Huo, Wei Wu, Xiaoliang Chen, et al. Deep learning-based multimodal data fusion in bone tumor management: Advances in clinical decision support[J]. Intelligent Oncology, 2025, 1(3): 204-215.DOI: 10.1016/j.intonc.2025.06.005.
Deep learning-based multimodal data fusion in bone tumor management: Advances in clinical decision support
and chondrosarcoma—are rare but biologically complex malignancies characterized by pronounced heterogeneity in anatomical location
histological subtype
and molecular alterations. Recent advances in artificial intelligence (AI)
particularly deep learning
have enabled the integration of diverse clinical data modalities to support diagnosis
treatment planning
and prognostication in bone oncology. This review provides a comprehensive synthesis of AI-driven multimodal fusion strategies that incorporate radiological imaging
digital pathology
multi-omics profiling
and electronic health records. We conducted a structured review of peer-reviewed literature published between 2015 and early 2025
focusing on the development
validation
and clinical applicability of AI models for BT diagnosis
subtyping
treatment response prediction
and recurrence monitoring. Although multimodal models have demonstrated advantages over unimodal approaches
especially in handling missing data and improving generalizability
most remain constrained by single-center study designs
small sample sizes
and limited prospective or external validation. Persistent technical and translational challenges include semantic misalignment across modalities
incomplete datasets
limited model interpretability
and regulatory and infrastructural barriers to clinical integration. To address these limitations
we highlight emerging directions such as contrastive representation learning
generative data augmentation
transformer-based fusion architectures
and privacy-preserving federated learning. We also discuss the evolving role of foundation models and workflow-integrated AI agents in enhancing scalability and clinical usability. In summary
multimodal AI represents a promising paradigm for advancing precision care in BTs. Realizing its full clinical potential will require methodologically rigorous
biologically informed
and system-level approaches that bridge algorithmic innovation with real-world healthcare delivery.
Abstract
Bone tumors (BTs)—including osteosarcoma
Ewing sarcoma
and chondrosarcoma—are rare but biologically complex malignancies characterized by pronounced heterogeneity in anatomical location
histological subtype
and molecular alterations. Recent advances in artificial intelligence (AI)
particularly deep learning
have enabled the integration of diverse clinical data modalities to support diagnosis
treatment planning
and prognostication in bone oncology. This review provides a comprehensive synthesis of AI-driven multimodal fusion strategies that incorporate radiological imaging
digital pathology
multi-omics profiling
and electronic health records. We conducted a structured review of peer-reviewed literature published between 2015 and early 2025
focusing on the development
validation
and clinical applicability of AI models for BT diagnosis
subtyping
treatment response prediction
and recurrence monitoring. Although multimodal models have demonstrated advantages over unimodal approaches
especially in handling missing data and improving generalizability
most remain constrained by single-center study designs
small sample sizes
and limited prospective or external validation. Persistent technical and translational challenges include semantic misalignment across modalities
incomplete datasets
limited model interpretability
and regulatory and infrastructural barriers to clinical integration. To address these limitations
we highlight emerging directions such as contrastive representation learning
generative data augmentation
transformer-based fusion architectures
and privacy-preserving federated learning. We also discuss the evolving role of foundation models and workflow-integrated AI agents in enhancing scalability and clinical usability. In summary
multimodal AI represents a promising paradigm for advancing precision care in BTs. Realizing its full clinical potential will require methodologically rigorous
biologically informed
and system-level approaches that bridge algorithmic innovation with real-world healthcare delivery.